It is assumed that the use of neuroprotective agents such as COX-2 inhibitors, P2X7 receptor antagonists, and CB2 agonists might exert beneficial effects in ALS pathology by slowing down the progressive damage to motor neurons [81, 92]. This evidence concerns the gene P2RX7 and amyotrophic lateral sclerosis.